CDER published an annual report on its 2018 drug safety priorities summarizing key safety programs and activities, program updates, and milestones. In FDA Voices, CDER Director Janet Woodcock highlights several of FDA’s ongoing efforts in drug safety science, surveillance, and oversight activities including key programs.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
